ASHWINI MEHTA: Open Payments
NPI 1174800908 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$40,294 in 90 payments from 14 companies in 2025. Trend: 2023 $2,144 · 2024 $2,784 · 2025 $40,294
Speaker / faculty: $27,738Consulting: $6,773Food & beverage: $2,935Travel & lodging: $2,849
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 45 | $39,133 |
| ABBVIE INC. | 17 | $355 |
| Gilead Sciences, Inc. | 9 | $183 |
| Amgen Inc. | 2 | $139 |
| Novo Nordisk Inc | 2 | $139 |
| Eisai Inc. | 3 | $79 |
| Intra-Sana Laboratories | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $63 |
| Fujifilm Healthcare Americas Corporation | 1 | $28 |
| Sequana Medical US Inc. | 1 | $24 |
Products named: REZDIFFRA, MAVYRET, UPLIZNA, Lenvima, IQIRVO, RELTONE 200 MG, UTASWAKO AFP-L3, GLYCATE.
Industry payments across TX — which companies pay providers there.
